- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03327610
Selecting the Best Ventilator Hyperinflation Settings (VHI1)
Selecting the Best Ventilator Hyperinflation Settings Based on Physiologic Markers: Randomized Controlled Study
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Background: Ventilator Hyperinflation (VHI) has been shown to be effective in improving respiratory mechanics, secretion removal, and gas exchange in mechanically ventilated patients; however, there are no recommendations on the best ventilator settings to perform the technique. Thus, the aim of this study was to compare six modes of VHI, concerning physiological markers of efficacy and safety criteria, in order to support the optimal VHI settings selection for mechanically ventilated patients.
Methods: In a crossover study, every included mechanically ventilated patient underwent six modes of VHI in a randomized order: Volume Control Continuous Mandatory Ventilation (VC-CMV) with inspiratory flow = 20Lpm (VC-CMV20), VC-CMV with inspiratory flow = 50Lpm (VC-CMV50), Pressure Control Continuous Mandatory Ventilation (PC-CMV) with inspiratory time = 1s. (PC-CMV1), PC-CMV with inspiratory time = 3s. (PC-CMV3), Pressure Support Ventilation (PSV) with cycling off = 10% of peak inspiratory flow (PSV10), and PSV with cycling off = 25% of peak inspiratory flow (PSV25). The maximum expansion (tidal volume), expiratory flow bias criteria (inspiratory and expiratory flow patterns), over-distension (alveolar pressure), asynchronies and hemodynamic variables (mean arterial pressure and heart rate) were assessed during the interventions.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients under mechanical ventilation for more than 48h
Exclusion Criteria:
- mucus hypersecretion (defined as the need for suctioning < 2-h intervals),
- absence of respiratory drive,
- atelectasis,
- severe bronchospasm,
- positive end expiratory pressure > 10cmH2O,
- PaO2-FiO2 relationship < 150,
- mean arterial pressure < 60mmHg,
- inotrope requirement equivalent to >15 ml/h total of adrenaline and noradrenalin,
- intracranial pressure > 20mmHg
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: BASELINE
The subjects were kept in their current ventilatory mode.
|
|
|
Experimental: VC-CMV20
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
|
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV).
The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
|
Experimental: VC-CMV50
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
|
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV).
The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
|
Experimental: PC-CMV1
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
|
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1).
The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
|
Experimental: PC-CMV3
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
|
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1).
The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
|
Experimental: PSV10
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
|
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV).
The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
|
Experimental: PSV25
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
|
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV).
The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Peak inspiratory to expiratory flow ratio
Periodo de tiempo: Ten minutes after the onset of intervention.
|
Dichotomous variable, defined as achieving a peak inspiratory flow rate (PIFR) less than 90% of the peak expiratory flow rate (PEFR)
|
Ten minutes after the onset of intervention.
|
|
Peak expiratory flow higher than 40 Lpm
Periodo de tiempo: Ten minutes after the onset of intervention.
|
Dichotomous variable, defined as achieving a PEFR higher than 40 l/min
|
Ten minutes after the onset of intervention.
|
|
Difference between peak inspiratory and expiratory flows.
Periodo de tiempo: Ten minutes after the onset of intervention.
|
Dichotomous variable, defined as achieving a difference higher than 17Lpm.
|
Ten minutes after the onset of intervention.
|
|
Pulmonary expansion
Periodo de tiempo: Ten minutes after the onset of intervention.
|
Percentage of tidal volume above the normal tidal volume (estimated as 6mL/kg).
|
Ten minutes after the onset of intervention.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean arterial pressure
Periodo de tiempo: Ten minutes after the onset of intervention.
|
Mean arterial pressure verified using the multi-parameter monitor.
|
Ten minutes after the onset of intervention.
|
|
Heart Rate
Periodo de tiempo: Ten minutes after the onset of intervention.
|
Heart rate verified using the multi-parameter monitor.
|
Ten minutes after the onset of intervention.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: FERNANDO S GUIMARAES, PhD, Centro Universitário Augusto Motta
Publicaciones y enlaces útiles
Publicaciones Generales
- Berney S, Denehy L. A comparison of the effects of manual and ventilator hyperinflation on static lung compliance and sputum production in intubated and ventilated intensive care patients. Physiother Res Int. 2002;7(2):100-8. doi: 10.1002/pri.246.
- Lemes DA, Zin WA, Guimaraes FS. Hyperinflation using pressure support ventilation improves secretion clearance and respiratory mechanics in ventilated patients with pulmonary infection: a randomised crossover trial. Aust J Physiother. 2009;55(4):249-54. doi: 10.1016/s0004-9514(09)70004-2.
- Thomas PJ. The effect of mechanical ventilator settings during ventilator hyperinflation techniques: a bench-top analysis. Anaesth Intensive Care. 2015 Jan;43(1):81-7. doi: 10.1177/0310057X1504300112.
- Ntoumenopoulos G, Shannon H, Main E. Do commonly used ventilator settings for mechanically ventilated adults have the potential to embed secretions or promote clearance? Respir Care. 2011 Dec;56(12):1887-92. doi: 10.4187/respcare.01229. Epub 2011 Jun 17.
- Anderson A, Alexanders J, Sinani C, Hayes S, Fogarty M. Effects of ventilator vs manual hyperinflation in adults receiving mechanical ventilation: a systematic review of randomised clinical trials. Physiotherapy. 2015 Jun;101(2):103-10. doi: 10.1016/j.physio.2014.07.006. Epub 2014 Oct 6.
- Davies JD, Senussi MH, Mireles-Cabodevila E. Should A Tidal Volume of 6 mL/kg Be Used in All Patients? Respir Care. 2016 Jun;61(6):774-90. doi: 10.4187/respcare.04651.
- de Wit M. Monitoring of patient-ventilator interaction at the bedside. Respir Care. 2011 Jan;56(1):61-72. doi: 10.4187/respcare.01077.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- VHI1
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre VC-CMV20
-
National Defense Medical Center, TaiwanTerminadoDolor, Agudo | Comportamiento infantil | Estrés fisiológico | La leche maternaTaiwán
-
ViaCyteCalifornia Institute for Regenerative Medicine (CIRM)TerminadoDiabetes mellitus tipo 1Canadá, Estados Unidos
-
ViaCyteTerminadoDiabetes tipo 1Estados Unidos
-
Sunnybrook Health Sciences CentreCanadian Initiative for Outcomes in Rheumatology CareTerminado
-
ViaCyteVertex Pharmaceuticals Incorporated; California Institute for Regenerative Medicine... y otros colaboradoresTerminadoDiabetes mellitus tipo 1 con hipoglucemiaEstados Unidos, Canadá, Bélgica
-
Queen's University, BelfastAWARE NI; Northern Ireland Public Health Research NetworkTerminado
-
ViaCyteTerminadoDiabetes mellitus tipo 1Canadá
-
University Medical Center GroningenTerminadoCáncer de esófagoPaíses Bajos
-
VA Office of Research and DevelopmentAún no reclutandoAfección pulmonar obstructiva crónicaEstados Unidos
-
International Centre for Diarrhoeal Disease Research...ReclutamientoEnsayo de no inferioridadBangladesh